You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The system is approved for use with the Procleix Ultrio Elite Assay, the Procleix WNV Assay, Procleix Zika Virus Assay, and the Procelix Babesia Assay.
The platform can detect a single virus in more than 1,000 samples at a time or more than 160 viruses, including SARS-CoV-2, in a small number of samples.
The company has developed a proof-of-concept single-pore sensor that it anticipates integrating into a prototype testing platform this year.
The Cobas Zika test is for use on Roche's Cobas 6800/8800 systems to screen blood donations and detects Zika virus RNA in samples of human plasma.
The company's Liaison XL Zika assay previously received Emergency Use Authorization from the FDA in 2017.
Two new grants are helping the company develop its SHERLOCK and INSPECTR technologies as the basis for creating innovative diagnostics.
The partners plan to validate the accuracy, effectiveness, and clinical implications of Group K's MultiNostic liver function test, which is pending FDA clearance.
The point-of-care diagnostics firm tallied $9.6 million in revenues in the second quarter, besting analysts' consensus estimate of $8.8 million.
The firm said that its multiplex point-of-care test uses 10 microliters of blood from a fingertip and provides quantitative results in about 15 minutes.
The funding will support development of a test for the Zika virus using Ontera's silicon nanopore-based molecular diagnostics platform.